Dapagliflozin is one of the SGLT-2 inhibiters. Recent clinical trials have demonstrated that SGLT-2 inhibitors are effective for treating heart failure. The DAPA-HF clinical trial has demonstrated that the effects of empagliflozin and dapagliflozin improve renal outcomes and reduce all-cause and cardiovascular death in patients with HFrEF\[1\]. However, its effect on myocardial infarction, the most common disease leading to death in the population, has not been evaluated sufficiently. A meta-analysis has demonstrated that compared with the control, SGLT2 inhibitor is associated with a reduction in the incidence of major adverse cardiovascular events (MACEs), myocardial infarction, cardiovascular mortality and all-cause mortality\[2\]. It seems that dapagliflozin might be effective for patients with acute myocardial infarction based on these studies. Thus, this study aims to evaluate the effect of dapagliflozin on short-term prognosis in patients with acute myocardial infarction compared to placebo. 1. Faiez Zannad, João Pedro Ferreira, Stuart J Pocock et el. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020 Sep 19;396(10254):819-829. 2. Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang et el. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Medicine (Baltimore). 2019 Dec;98(49):e18245.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
143
patients meeting inclusion criteria will be randomized to receive dapagliflozin 10 mg every 24 hours for 6 months
patients meeting the inclusion criteria will be randomized to receive AMI standard therapy every 24 hours for 12 months.
Mengmei Li
Qingdao, Shandong, China
MACE events
To assess the occurence of myocardial infarction, stroke and death from cardiovascular causes in post-infarction patients during the follow-up time.
Time frame: 12 months
Post-infarction angina
Evaluate the post-infarction angina occurence in both groups
Time frame: 12 months
The rate of heart failure occurrence
Assess the rate of new-onset heart failure during the study follow-up.
Time frame: 12 months
IL-6
Serum IL-6 level
Time frame: baseline, 1 month, 3 month, 6 month, 12 month
IL-1β
Serum IL-1β
Time frame: baseline, 1 month, 3 month, 6 month, 12 month
hs-CRP
hs-CRP
Time frame: baseline, 1 month, 3 month, 6 month, 12 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.